Secukinumab, CAS 1229022-83-6

Description: Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

CAS Number: 1229022-83-6

References: Frieder J, et al.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Ther Adv Chronic Dis. 2018 Jan;9(1):5-21.

• Artikelnummer: TGMT9930-1mg
• Hersteller: TargetMol Chemicals
• Hersteller Artikelnummer: T9930-1mg
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK